Drug-resistant typhoid strains are a growing problem in Cambodia, regionally, and across the globe.

Global data show that the multidrug-resistant (MDR) H58 typhoid strain prevalence has increased dramatically since 1992.\(^2\)

A study found that typhoid in Cambodian children is dominated by the H58 strain. Additionally, 85% of the isolates analyzed were MDR, leading the authors to conclude that drug-resistant typhoid is common in Cambodian children and therapeutic options are limited.\(^3\)

Another study found that the majority of isolates tested were MDR, and 80% had reduced susceptibility to ciprofloxacin, the standard treatment for typhoid in many parts of the world.

As drug-resistant typhoid becomes more common, it will become more difficult to treat and force the use of more expensive and less readily-available treatment options.
Typhoid conjugate vaccines in Cambodia

Tybar-TCV® is a newly licensed and World Health Organization (WHO)-prequalified and recommended tool for typhoid prevention in endemic areas. Gavi, the Vaccine Alliance support for introduction is available now.

Tybar-TCV is highly effective and safe for children as young as 6 months of age, and:

- Only requires one dose;
- May be more effective and longer-lasting than other previous typhoid vaccines; and
- Can be co-administered with measles-rubella vaccine.

Preliminary findings from an economic analysis predict that, even in the absence of a Gavi subsidy, a catch-up campaign with TCV could be potentially cost-effective in Cambodia.

Let’s Take on Typhoid in Cambodia

- Typhoid is endemic in Cambodia, with more than 31,000 cases per year.
- Cambodia’s burden of typhoid is most heavily borne by children younger than 15 years of age.
- Data show an increase in drug-resistant typhoid in Cambodia and globally.
- A new TCV is safe, effective, and WHO-recommended for routine immunization as part of a cost-effective, integrated approach to typhoid prevention and control alongside safe water, sanitation, and hygiene interventions.
- Gavi support for TCV introduction is available now.